Prenatal pertussis vaccination slips to a new low in England
England’s prenatal pertussis vaccination programme ended the July to September 2022 quarter at 60.2% coverage, marking a continued decline in protection for pregnant women and the infants who depend on passive antibody transfer before their own vaccine course begins. Monthly uptake held near that level across the quarter, at 60.2% in July, 59.8% in August and 60.8% in September, but the steadiness masks a broader drop that has now pushed coverage to the lowest level recorded since the current data specification began in April 2016.
The public health stakes are straightforward. Pertussis is most dangerous in very young infants, especially before the first routine dose at 8 weeks of age, and maternal vaccination is designed to fill that immunologic gap by moving antibodies across the placenta during pregnancy. When uptake falls, the programme loses reach precisely where it matters most: in the final stretch before birth, when a newborn remains too young to generate active protection.
Coverage gap widens against recent years and long-term benchmarks
Mean coverage for the quarter was 4.7 percentage points lower than the same quarter in 2021 to 2022 and 6.4 percentage points lower than the same quarter in 2020 to 2021. The decline is not a small fluctuation around a stable baseline; it is a sustained reversal from prior years that began before the quarter under review and continued through September 2022. In practical terms, fewer pregnant women were vaccinated after 16 weeks’ gestation, leaving a larger share of infants without the antibody shield that the programme is meant to provide.
A one-sentence reality sits at the center of the data: coverage in this quarter was the lowest measured since the 2016 change that allowed earlier vaccination in pregnancy.
That matters because the programme’s operational design already expanded the window for vaccination to increase opportunity without reducing infant protection. Earlier eligibility from 16 weeks, with an ideal window around 20 weeks or after the anomaly scan, was intended to make delivery of the vaccine easier, not harder. A fall to the weakest quarterly performance since that policy change suggests the barrier is not a narrow timing issue alone, but a broader failure of delivery, access, or uptake within routine maternity and primary care pathways.
London drives most of the national decline
The clearest geographic signal comes from London, where coverage has steadily fallen behind the rest of England. In September 2022, London NHS commissioning region had coverage 9.0 percentage points lower than in September 2020, and the region has now dropped 22.1 percentage points from 60.9% in December 2019 to 38.8% in September 2022. Across England, the gap between the highest-performing region and London widened to 29 percentage points this quarter, up from a 20.9-point difference in quarter 2 of 2019 to 2020.
The regional spread is large enough to suggest that local service organization is shaping outcomes as much as vaccine acceptance itself. North East and Yorkshire remained the highest-performing region, while London fell further away with each reporting cycle. Within integrated care boundaries, the range was even more striking: coverage varied from 25.5% in North Central London in August to 80.9% in Derby and Derbyshire in July. Such variation points to different levels of vaccination capture in antenatal care, differences in recording completeness, and uneven success in reaching pregnant women before delivery.
Primary care data capture remains essential to the estimate
Coverage estimates were drawn from automated monthly data uploads from participating GP IT suppliers to the ImmForm system, with validation by the UK Health Security Agency to check completeness and identify anomalous records. The numerator included women vaccinated between week 16 of pregnancy and delivery, while the denominator included women who delivered in the survey month, excluding miscarriages and stillbirths. For the figures to be accurate, the underlying medical record must be complete, including the delivery date, the date of pertussis vaccination at or after week 16, and any relevant record of stillbirth or miscarriage.
Those details are not administrative trivia. They determine whether a vaccine delivered in maternity care, general practice, or another setting is counted in the national estimate. If the record is incomplete, real-world protection can be missed by the surveillance system, which makes any decline in participation or data quality more consequential.
Participation was strong in July and August, then fell sharply in September
National GP practice participation was 96.9% in July, 96.1% in August and 67.1% in September 2022. All GP IT suppliers provided data for the quarter, but the September dip in practice participation complicates interpretation of the month-specific figure and introduces a cautionary note for trend analysis. Even so, the quarter’s mean coverage remained low across all three months, and the broader downward pattern predates September’s weaker participation rate.
The distribution by integrated care board also shows that low national coverage is not a simple artifact of one outlier region. Some areas remained above 70%, including Norfolk and Waveney at 73.8% for the quarter and Shropshire, Telford and Wrekin at 77.7%. Others sat far below the national average, including Birmingham and Solihull at 45.8%, South East London at 48.3%, and North Central London at 26.1%. Such dispersion is the fingerprint of an uneven public health programme rather than a uniform countrywide shift.
Maternal vaccination remains the critical defense for newborns
The clinical logic behind the programme is unchanged even as uptake slips. Maternal immunisation creates an antibody bridge between birth and infant vaccination, reducing the likelihood that a newborn encounters pertussis during the most vulnerable early weeks of life. When coverage remains around 60% nationally, a substantial share of pregnant women do not receive that bridge, and the population-level buffer against severe infant disease thins accordingly.
No new safety signal appears in these data; the problem is reach, not toxicity. The report instead documents a service gap in routine prevention, with London carrying the heaviest burden of undercoverage and the national average drifting to its lowest point in years. Future quarterly surveillance will need to show whether local delivery improvements, better antenatal integration, and more consistent vaccine recording can reverse the decline before another cohort of infants is born without this layer of protection.